FDA-cleared contactless patient monitoring with predictive AI
Circadia deploys contactless respiratory monitoring hardware paired with ML-driven clinical analytics to detect patient deterioration hours or days early. The tech stack reveals a predictive-analytics focus: XGBoost, LightGBM, CatBoost, and SHAP dominate the ML layer, while HL7/FHIR and Airflow orchestrate EHR and device-telemetry pipelines. Active projects span time-series modeling, feature engineering, and clinical talent scaling — signaling a company transitioning from device-centric to outcome-prediction platform, with hiring velocity accelerating across engineering and healthcare roles.
Notable leadership hires: Director of Operations
Circadia manufactures an FDA-cleared contactless monitoring device that detects respiratory rate from up to 8 feet away, enabling early warning for conditions like sepsis, pneumonia, heart failure exacerbations, and falls. The product integrates device telemetry, electronic health records, and predictive models to surface risk alerts through a virtual nursing team. Customers are skilled nursing facilities and acute-care settings where readmission reduction and clinical operations improvement are core metrics. The company is based in Los Angeles and operates in the US and UK; current hiring emphasizes engineering depth (predictive models, pipelines, backend reliability) alongside clinical and operations leadership.
An FDA-cleared contactless monitoring system that detects respiratory rate from up to 8 feet away, combined with ML models (XGBoost, LightGBM, CatBoost) that predict clinical events like sepsis, pneumonia, heart failure, and falls hours or days in advance.
ML models (XGBoost, LightGBM, CatBoost, SHAP), cloud platforms (AWS, GCP), healthcare standards (HL7, FHIR, REST, SFTP), and orchestration (Apache Airflow, AWS Batch, MLflow) for EHR integration and device telemetry pipelines.
Other companies in the same industry, closest in size